All products for:HIV Diagnostics&ManagementImmunoassayEmergency and Critical CareHIVInfectious Diseases
  • VIDAS HIV panel

VIDAS® HIV panel

Advanced 4th generation assays for earlier diagnosis

The VIDAS® HIV panel provides a combination of advanced 4th generation assays for improved detection of acute HIV during the critical “window period”.

  • Combined detection of anti-HIV-1 (groups M and O) and anti-HIV-2 total immunoglobulins + HIV-1 p24 antigen
  • True dual information: differentiation of Ag and Ab signals
  • Highest p24 Ag sensitivity currently available
  • Easy-to-use solution
Add to my selection

Do you need more information

Contact us

Many of the 35.3 million people infected with HIV worldwide are unaware of their condition, as symptoms may be absent or non-specific. In addition, there is a mean period of 3 weeks between contamination and the appearance of the first anti-HIV serum antibodies1. Early detection of seroconversions is thus one of the main HIV diagnostic challenges.

The VIDAS® automated HIV infection screening tests allow simultaneous detection of p24 antigen and anti-HIV antibodies enabling the time lapse between contamination and diagnosis of the infection to be decreased. Identifying more primary infections can make a key difference in reducing transmission. Providing appropriate therapy as fast as possible is also essential to improve patient outcome.

A unique assay concept

The VIDAS® HIV panel:

 

vidas-hiv-panel_2.png

Show in media library: 

 

Assay concept:


Click to enlarge »

 

Excellent performances

  • Best analytical sensitivity compared to other commonly-used assays2,3
  • Lowest limit of detection of HIV infection2,3
  • Highest p24 Ag sensitivity currently available (Lower Limit of Detection against the WHO standard):
    • VIDAS® HIV Duo Ultra: 0.66 IU/mL3
    • VIDAS® HIV Duo Quick: 0.43 IU/mL3
    • VIDAS® HIV P24:0.73 - 1.15 IU/mL3

Ease of use and flexibility for your lab

  • Easy-to-use solution
  • One patient, one strip
  • Renowned VIDAS® robustness and reliability

References:

  1. Kleinman S., et al. Transfusion Medicine Reviews. July 1997. Vol. 11, N° 3 p. 155-172.
  2. Ly TD, et al. 2007 Jul; 143(1):86-94. Epub 2007 Mar 28.
  3. Miedouge M, et al. J Clin Virol. 2011 Jan;50(1):57-60. doi: 10.1016/j.jcv.2010.09.003.

 

  VIDAS® HIV
DUO Ultra		 VIDAS® HIV
DUO Quick		 VIDAS® P24 II
Reference 30443 30447 30117
Tests / kit 60 60 30
Sample type Serum or plasma on lithium heparinate or EDTA
Sample volume 200 µL
Calibration & control stability 14 days
Results Separated results for
Ag and Ab		 Global results  
Sensitivity in Ag 11.5 pg/ml HIV Ag 16.5 pg/ml HIV Ag 11.25 pg/ml HIV Ag

 

  VIDAS® HIV P24 II Confirmation
Reference 30 444
Tests  / kit 60 tests

 

Find more technical details on www.myvidas.com.

Consult your local bioMérieux representative for product availability in your country.

Related Publications

Guidelines

 

Find more scientific and educational resources on www.myvidas.com.

Pioneering Diagnostics